AMRX vs HIK.L
AMRX: A diversified biopharmaceutical company providing a broad range of generic, branded, and specialty medicines alongside pharmaceutical distribution services. HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets.
Side-by-side fundamentals
| Metric | AMRX | HIK.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $18.46 | £15.73 | |
| Market cap as of 2026-08-06 | $5.9B | n/a | |
| P/E as of 2026-08-06 | 48.27 | n/a | |
| PEG as of 2026-08-06 | 2.85 | n/a | |
| Net margin as of 2026-08-06 | +4.0% | n/a | |
| Gross margin as of 2026-08-06 | +38.7% | n/a | |
| Operating margin as of 2026-08-06 | +14.3% | n/a | |
| ROE as of 2026-08-06 | -34.9% | n/a | |
| ROA as of 2026-08-06 | +3.4% | n/a | |
| Debt / equity as of 2026-08-06 | 136.58 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | +7.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +10.9% | n/a | |
| Beta as of 2026-08-06 | 1.25 | n/a | |
| 1-year return as of 2026-08-05 close | +127.1% | -18.9% | AMRX higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.